ALKS - Alkermes plc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

4.109B

Cash

876.1M

Avg Qtr Burn

N/A

Short % of Float

10.31%

Insider Ownership

1.26%

Institutional Own.

-

Qtr Updated

06/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Aristada (aripiprazole lauroxil) Details Schizophrenia, Mental health	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vivitrol (naltrexone) Details Alcohol dependence, Opioid dependence	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LYBALVI (ALKS 3831) Details Bipolar disease, Schizophrenia, Mental health	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALKS 2680 (RDC-264177) ( Orexin 2 Receptor Agonist) Details EDS in Idiopathic Hypersomnia , Narcolepsy	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.